drugset / Trial / NCT05992428

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

NCT05992428

Phase 1 Completed 37 enrolled Dong-A ST Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, 2-Part, phase 1 study to evaluate drug interactions when DA-8010 is co-administered with Paroxetine or Mirabegron in healthy adult subjects

Timeline

Start
2023-08-22
Primary completion
2023-11-07
Completion
2023-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 50 mg
Subject Paroxetine Small molecule 20 mg
Subject VELUFENACIN Small molecule 5 mg

Indications

No indication recorded.